E112D polymorphism in the prolylcarboxypeptidase gene is associated with blood pressure response to benazepril in Chinese hypertensive patients

Chinese Medical Journal

Volumn 122, Issue 20, 2009, Pages 2461-2465

  Zhang, Yan ^a   Hong, Xiu Mei ^b   Xing, Hou Xun ^b   Li, Jian Ping ^a   Huo, Yong ^a   Xu, Xi Ping ^b  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Benazepril; Hypertension; Polymorphism; Prolylcarboxypeptidase

Indexed keywords

ASPARTIC ACID; BENAZEPRIL; GLUTAMIC ACID; PROLINE CARBOXYPEPTIDASE;

ADULT; ARTICLE; CHINA; CHINESE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG RESPONSE; ESSENTIAL HYPERTENSION; FEMALE; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC POLYMORPHISM; GENOTYPE; GEOGRAPHY; HETEROZYGOTE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PREDICTION; SHORT COURSE THERAPY; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BENZAZEPINES; BLOOD PRESSURE; CARBOXYPEPTIDASES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; YOUNG ADULT;

EID: 70350712457     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2009.20.012     Document Type: Article

References (21)

1. Balfour JA, Goa KL. Benazepril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure. Drugs 1991; 42: 511-539.
2. Schwarz UI, Ritchie MD, Bradford Y, Li C, Dudek SM, Frye-Anderson A, et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008; 358: 999-1008. (Pubitemid 351347099)
3. Dishy V, Sofowora GG, Xie HG, Kim RB, Byrne DW, Stein CM, et al. The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization. N Engl J Med 2001; 345: 1030-1035. (Pubitemid 34940795)
4. Psaty BM, Smith NL, Heckbert SR, Vos HL, Lemaitre RN, Reiner AP, et al. Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. JAMA 2002; 287: 1680-1689.
5. Jiang S, Mao G, Zhang S, Hong X, Tang G, Li Z, et al. Individual and joint association of alpha1A-adrenergic receptor Arg347Cys polymorphism and plasma irbesartan concentration with blood pressure therapeutic response in Chinese hypertensive subjects. Clin Pharmacol Ther 2005; 78: 239-248. (Pubitemid 41254109)
6. Mallela J, Yang J, Shariat-Madar Z. Prolylcarboxypeptidase: A cardioprotective enzyme. Int J Biochem Cell Biol 2009; 41: 477-481.
7. Watson B Jr, Nowak NJ, Myracle AD, Shows TB, Warnock DG. The human angiotensinase C gene (HUMPCP) maps to 11q14 within 700 kb of D11S901: A candidate gene for essential hypertension. Genomics 1997; 44: 365-367.
8. Wang L, Feng Y, Zhang Y, Zhou H, Jiang S, Niu T, et al. Prolylcarboxypeptidase gene, chronic hypertension, and risk of preeclampsia. Am J Obstet Gynecol 2006; 195: 162-171. (Pubitemid 43927535)
9. Li D, Xing H, Hao K, Peng S, Wu D, Guang W, et al. Hypertensive patients from two rural Chinese counties respond differently to benazepril: the Anhui hypertension health care study. Ann Epidemiol 2004; 14: 123-128. (Pubitemid 38221170)
10. Massie BM. Demographic considerations in the selection of antihypertensive therapy. Am J Cardiol 1987; 60: 121I-126I.
11. Weinshilboum R. Inheritance and drug response. N Engl J Med 2003; 348: 529-537.
12. Evans WE, McLeod HL. Pharmacogenomics - drug disposition, drug targets, and side effects. N Engl J Med 2003; 348: 538-549. (Pubitemid 36159890)
13. Su X, Lee L, Li X, Lü J, Hu Y, Zhan S, et al. Association between angiotensinogen, angiotensin II receptor genes, and blood pressure response to an angiotensin-converting enzyme inhibitor. Circulation 2007; 115: 725-732. (Pubitemid 46294763)
14. Hingorani AD, Jia H, Stevens PA, Hopper R, Dickerson JE, Brown MJ. Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition. J Hypertens 1995; 13(12 Pt 2): 1602-1609.
15. Yu H, Lin S, Liu G, Zhang Y, Deng C, Ma W. T1198C polymorphism of the angiotensinogen gene and antihypertensive response to angiotensin-converting enzyme inhibitors. Hypertens Res 2005; 28: 981-986. (Pubitemid 43298999)
16. Mondorf UF, Russ A, Wiesemann A, Herrero M, Oremek G, Lenz T. Contribution of angiotensin I converting enzyme gene polymorphism and angiotensinogen gene polymorphism to blood pressure regulation in essential hypertension. Am J Hypertens 1998; 11: 174-183.
17. Odya CE, Marinkovic DV, Hammon KJ, Stewart TA, Erdös EG. Purification and properties of prolylcarboxypeptidase (angiotensinase C) from human kidney. J Biol Chem 1978; 253: 5927-5931.
18. Shariat-Madar Z, Mahdi F, Schmaier AH. Recombinant prolylcarboxypeptidase activates plasma prekallikrein. Blood 2004; 103: 4554-4561. (Pubitemid 38750184)
19. Shariat-Madar Z, Rahimy E, Mahdi F, Schmaier AH. Overexpression of prolylcarboxypeptidase enhances plasma prekallikrein activation on Chinese hamster ovary cells. Am J Physiol Heart Circ Physiol 2005; 289: H2697-H2703.
20. Zhao Y, Qiu Q, Mahdi F, Shariat-Madar Z, Røjkjaer R, Schmaier AH. Assembly and activation of HK-PK complex on endothelial cells results in bradykinin liberation and NO formation. Am J Physiol Heart Circ Physiol 2001; 280: H1821-H1829. (Pubitemid 32466219)
21. Banzet O, Colin JN, Thibonnier M, Singlas E, Alexandre JM, Corvol P. Acute antihypertensive effect and pharmacokinetics of a tablet preparation of nifedipine. Eur J Clin Pharmacol 1983; 24: 145-150. (Pubitemid 13147702)